Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3BCHECHRM1CHRM2CHRM3CHRM4CHRNA3CHRNA4CHRNB2CHRNB4ESR1ESR2GABRA1GABRB1GABRG2GBA1GHSRHRH1HTR1DHTR2AMAOBOPRD1OPRK1OPRM1SLC6A2SLC6A3TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8UGCGrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Cadaverine Tartrate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | CA4 | P22748 | 5/20 | 0.43 |
| ▸ | FAHD1 | Q6P587 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | LDHA | P00338 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cadaverine Tartrate SCHEMBL80796 | 1.00 | TSHR (0.47) | TSHRLMNACA4FAHD1BLM | |
| Cadaverine Tartrate SCHEMBL29499522 | 1.00 | TSHR (0.47) | TSHRLMNACA4FAHD1BLM | |
| Cadaverine Tartrate SCHEMBL3858 | 0.96 | CA4 (0.50) | TSHRLMNACA4FAHD1BLM | |
| Cadaverine Tartrate SCHEMBL1314700 | 0.96 | TSHR (0.44) | TSHRLMNACA4FAHD1BLM | |
| Cadaverine Tartrate SCHEMBL11224455 | 0.96 | TSHR (0.44) | TSHRLMNACA4FAHD1BLM | |
| Cadaverine Tartrate SCHEMBL11525885 | 0.96 | TSHR (0.44) | TSHRLMNACA4FAHD1BLM | |
| Cadaverine Tartrate SCHEMBL8766108 | 0.96 | TSHR (0.44) | TSHRLMNACA4FAHD1BLM | |
| Cadaverine Tartrate SCHEMBL1438667 | 0.96 | TSHR (0.44) | TSHRLMNACA4FAHD1BLM | |
| Cadaverine Tartrate SCHEMBL1434088 | 0.96 | TSHR (0.44) | TSHRLMNACA4FAHD1BLM | |
| Cadaverine Tartrate SCHEMBL330144 | 0.96 | TSHR (0.44) | TSHRLMNACA4FAHD1BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12636328-B2 | Probiotics complex composition with immunomodulatory and immune homeostasis property | LACTOMASON CO., LTD. (KR) | 2026-05-26 | — | — | US | disclosed |
| US-12629372-B2 | Development of combined therapeutic agent for fibrotic disease | KOREA INSTITUTE OF RADIOLOGICAL & MEDICAL SCIENCES (KR) | 2026-05-19 | — | — | US | disclosed |
| EP-4169923-B1 | NOVEL PROLYL FK506 DERIVATIVES HAVING NEURITE GROWTH AND SYNAPSE FORMATION ACTIVITIES AND USES THEREOF | MOLGENBIO CO LTD (KR) | 2026-02-25 | — | — | EP | disclosed |
| EP-4129298-B1 | COMPOSITE PHARMACEUTICAL COMPOSITION FOR TREATMENT OF FIBROSIS DISEASE | KOREA INST RADIOLOGICAL & MEDICAL SCIENCES (KR) | 2026-02-11 | — | — | EP | disclosed |
| US-12527824-B2 | Strain of Bifidobacterium animalis subsp. lactis HEM20-01 and composition for treating depression, comprising the same or its culture fluid | HEM PHARMA INC. (KR) | 2026-01-20 | — | — | US | disclosed |
| US-12428620-B2 | Strain of Lactobacillus sakei HEM224, and composition for treating inflammation or asthma comprising strain or cultured product thereof | HEM PHARMA INC. (KR) | 2025-09-30 | — | — | US | disclosed |
| EP-4620311-A1 | METHOD FOR PRODUCING RETORT FOOD BROTH COMPOSITION HAVING ENHANCED AROMA AND FLAVOR | CJ CheilJedang Corporation (KR) | 2025-09-24 | — | — | EP | disclosed |
| EP-4606884-A1 | NOVEL AUREOBASIDIUM PULLULANS STRAIN FOR HIGH-EFFICIENCY PRODUCTION OF OLIGOSACCHARIDES AND USE THEREOF | CJ CheilJedang Corporation (KR) | 2025-08-27 | — | — | EP | disclosed |
| US-20250228901-A1 | COMPOSITION FOR PREVENTING, ALLEVIATING OR TREATING INFLAMMATORY SKIN DISEASES, COMPRISING CUTIBACTERIUM SP. STRAIN | CJ BIOSCIENCE, INC. (KR) | 2025-07-17 | — | — | US | disclosed |
| US-20250213632-A1 | COMPOSITION FOR AMELIORATING SIDE EFFECTS CAUSED BY CANCER TREATMENT COMPRISING LACTOBACILLUS FERMENTUM HEM1036 STRAIN AS ACTIVE INGREDIENT | HEM PHARMA INC. (KR) | 2025-07-03 | — | — | US | disclosed |
| US-20220211821-A1 | COMPOSITION FOR PREVENTING OR TREATING OBESITY, COMPRISING PHOSPHOLIPASE A2 AS ACTIVE INGREDIENT | TWINPIG BIOLAB, INC. (KR) | 2022-07-07 | — | — | US | disclosed |
| US-11376310-B2 | Pharmaceutical composition for preventing or treating dentin-dental pulp diseases or periodontal disease including CPNE4 protein | HYSENSBIO (KR) | 2022-07-05 | — | — | US | disclosed |
| US-20220204776-A1 | PROCESS FOR PREPARING A LAWSONIA INERMIS EXTRACT | PIERRE FABRE DERMO-COSMETIQUE (FR) | 2022-06-30 | — | — | US | disclosed |
| US-20220192971-A1 | DYE COMPOSITION COMPRISING A COMBINATION OF TWO PLANT EXTRACTS OF LAWSONIA INERMIS | PIERRE FABRE DERMO-COSMETIQUE (FR) | 2022-06-23 | — | — | US | disclosed |
| US-11319279-B2 | Antimicrobial compound and use thereof | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2022-05-03 | — | — | US | disclosed |
| EP-3984373-A1 | COMPOSITION FOR PREVENTING, TREATING, OR IMPROVING GASTROINTESTINAL DISEASES COMPRISING STRAIN OF GENUS CORYNEBACTERIUM AND CULTURE THEREOF | CJ Cheiljedang Corporation (KR) | 2022-04-20 | — | — | EP | disclosed |
| EP-3983487-A1 | PROCESS FOR PREPARING A LAWSONIA INERMIS EXTRACT | Pierre Fabre Dermo-Cosmétique (FR) | 2022-04-20 | — | — | EP | disclosed |
| EP-3983488-A1 | DYE COMPOSITION COMPRISING A COMBINATION OF NATURAL DYEING AGENTS INCLUDING AN EXTRACT OF LAWSONIA INERMIS | Pierre Fabre Dermo-Cosmétique (FR) | 2022-04-20 | — | — | EP | disclosed |
| EP-3984545-A1 | FOOD COMPOSITION FOR PROMOTING HEIGHT GROWTH AND PHARMACEUTICAL COMPOSITION FOR PROMOTING HEIGHT GROWTH INCLUDING HUMULUS JAPONICUS EXTRACT OR GROUND HUMULUS JAPONICUS AS ACTIVE INGREDIENT | Pens Co., Ltd. (KR) | 2022-04-20 | — | — | EP | disclosed |
| EP-3964228-A1 | COMPOSITION FOR PREVENTING OR TREATING OBESITY, COMPRISING PHOSPHOLIPASE A2 AS ACTIVE INGREDIENT | UNIVERSITY-INDUSTRY COOPERATION GROUP OF KYUNG HEE UNIVERSITY (KR) | 2022-03-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11319279-B2 | Antimicrobial compound and use thereof | AAAS, VRK1, CACNA1E | TSHR 4449/4885LMNA 2209/4885CA4 440/4885 |
| US-20220204776-A1 | PROCESS FOR PREPARING A LAWSONIA INERMIS EXTRACT | KRT18, LMNB1, CKMT1A; CKMT1B | TSHR 4838/4885LMNA 9/4885CA4 2719/4885 |
| US-12636328-B2 | Probiotics complex composition with immunomodulatory and immune homeostasis property | LPO, LCT, LENG8 | TSHR 2944/4885LMNA 4309/4885CA4 3656/4885 |
| US-20220192971-A1 | DYE COMPOSITION COMPRISING A COMBINATION OF TWO PLANT EXTRACTS OF LAWSONIA INERMIS | KRT18, DSG1, LMNB2 | TSHR 4633/4885LMNA 88/4885CA4 1231/4885 |
| US-12527824-B2 | Strain of Bifidobacterium animalis subsp. lactis HEM20-01 and composition for treating depression, comprising the same or its culture fluid | CRH, CRHBP, LRBA | TSHR 1272/4885LMNA 2498/4885CA4 4154/4885 |
| US-12629372-B2 | Development of combined therapeutic agent for fibrotic disease | FIBP, HGF, COL1A1 | TSHR 2164/4885LMNA 1275/4885CA4 3739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.